872366-87-5Relevant academic research and scientific papers
Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists
Buil, Maria Antonia,Calbet, Marta,Castillo, Marcos,Castro, Jordi,Esteve, Cristina,Ferrer, Manel,Forns, Pilar,González, Jacob,López, Sara,Roberts, Richard S.,Sevilla, Sara,Vidal, Bernat,Vidal, Laura,Vilaseca, Pere
, p. 102 - 133 (2016/03/04)
Monocyclic and bicyclic ring systems were investigated as the "core" section of a series of diphenylsulphone-containing acetic acid CRTh2 receptor antagonists. A range of potencies were observed and single-digit nanomolar potencies were obtained in both the monocyclic and bicyclic cores. Residence times for the monocyclic compounds were very short. Some of the bicyclic cores displayed better residence times. A methyl group in the northern part of the core, between the head and tail was a necessary requirement for the beginnings of long residence times. Variations of the tail substitution maximised potencies and residence times.
Heterocyclic compounds
-
Paragraph 0189-0192, (2016/11/07)
The present invention relates to a novel heterocyclic compound or to pharmaceutically acceptable salts and solvates thereof. The pharmaceutical composition or cosmetic composition comprising, as active ingredients, the compound or pharmaceutically acceptable salts and solvates thereof may be effectively used in the treatment or prevention of skin diseases.
USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN
-
Page/Page column 59, (2008/06/13)
There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use in the manufacture of a medicament for the treatment of neuropathic pain.
ORGANIC COMPOUNDS
-
Page/Page column 64, (2010/02/15)
There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
